Microsoft word - encv_prof zipp.docx

Frauke Zipp
Professor of Neurology
Johannes Gutenberg University Medical Center Mainz

Research Profile
After studying Medicine in Germany, the USA, Canada and England, Frauke Zipp
began her scientific career at the MPI Martinsried with Hartmut Wekerle in
Neuroimmunology. During clinical training with Johannes Dichgans in Tübingen, she
was a visiting scientist at the NIH. After a decade at the Charité, she is currently
Director of the Department of Neurology at the University Medical Center Mainz. She
is spokesperson of a Col aborative Research Center on Multiple Sclerosis, Executive
Board Member of the Competence Network of Multiple Sclerosis (KKNMS), Council
Member of ECTRIMS and Board Member of the International Society of
Neuroimmunology (ISNI) as wel as Conference Chair of ISNI in 2014 in Germany.
Frauke Zipp performed several IITs, contributed to a large series of clinical trials and
participated in steering as wel as data monitoring committees of clinical trials.
General Information
Name:
Department of Neurology Johannes Gutenberg University Mainz Langenbeckstr. 1, 55131 Mainz Tel.: +49-6131-17 7156 Fax: +49-6131-17 5697 E-mail: [email protected] Homepage: http://www.unimedizin-mainz.de/neurologie/
Education
1982 – 1989
Medicine, J.W. Goethe University, Frankfurt, Germany; Studies in North America (North Carolina; Toronto) and England (Royal Free, London) Residency in Neurology, J.W. Goethe Univ., Frankfurt (Prof. Fischer)
Degrees and awards
1986 – 1990
Medical thesis (Dr. med.), Anatomy, J.W. Goethe Univ., Frankfurt, Prof. M. Frotscher Research Prize from the DCP Akademie for Clinical Diagnosis Nils-Ilja-Richter Preis for Lancet work 2003 Pette-Prize from the Society of Neurology Germany Member German National Academy of Sciences Leopoldina
Professional Experience
1993 – 1995
Postdoctoral Fel ow, Dept. of Neuroimmunology, Max Planck Institute, Martinsried, Germany (Profs. H. Wekerle and R. Hohlfeld) Fel owship and “Habilitation” in Neurology, Department of Neurology at Eberhard Karls University, Tübingen, Germany, Prof. J. Dichgans Visiting Scientist, National Institute of Health, Division of Neuroimmunology, Bethesda, MD, USA, Prof. H. McFarland Senior Physician, Dept. of Neurology, Charité, Berlin C3-Professor; Head of the Institute of Neuroimmunology, Charité, Berlin, Research Section at Campus Mitte and Clinic at Campus Buch W3-Professor (Ful Professor) at the Charité - University Hospital Berlin; and Clinical Coordinator and Board Director at the Max-Delbrück-Center for Molecular Medicine (Helmholtz); Director of the Cecilie-Vogt-Klinik, Charité 2006-2009 (move) Spokesperson of GRK 1258 “Influence of inflammation on 2007-2009 (move) Board Director of the Excel ence Cluster “NeuroCure” and Participant in the Graduate School of Excel ence for Regenerative Therapy (BSRT) 2008-2009 (move) Spokesperson of the Transregio CRC TR 43 “The brain as a W3-Professor (Ful Professor) for Neurology and Director of the Department of Neurology, University Medical Center Mainz, Johannes Gutenberg University Mainz Spokesperson of the Col aborative Research Center on Multiple Sclerosis CRC TR 128 (German Research Council DFG) Other professional activities
Member of the Medical Advisory Board of the German Multiple Sclerosis Society;
Member of the Executive Board of the Rheinland Pfalz Multiple Sclerosis Society;
Member of ECTRIMS Council;
Member of the Gutenberg-Forschungs-Kol eg;
Executive Board Member of the Kompetenznetz Multiple Sklerose (KKNMS, Ministry
of Science BMBF);
Member of Board of the International Society of Neuroimmunology (ISNI);
Member of the International Advisory Boards of the Institute for Brain and Spinal
Cord Diseases of the University Hospital Pitié-Salpetrière, Paris
Member of the Multiple Sclerosis International Federation (MSIF)

SELECTED PUBLICATIONS

Zipp F, Gold R, Wiendl H. 2013. Identification of inflammatory neuronal injury and
prevention of neuronal damage in Multiple Sclerosis – hope for novel therapies?
JAMA Neurol, in press
Liblau R, Gonzalez-Dunia D, Wiendl H, Zipp F. 2013. Neurons as targets for T cel s
in the nervous system. Trends Neurosci 36:315-324

IMSGC, last and corresponding author: Zipp F. 2013. MANBA, CXR5, SOX8,
RPS6KB1 and ZBTB46 are genetic risk loci for multiple sclerosis. Brain 136:1778-82
Methner A, Zipp F. 2013. Multiple Sclerosis in 2012: Novel therapeutic options and
drug targets in MS. Nat Rev Neurol 9:72-3
Jolivel V, Luessi F, Masri J, Kraus S, Hubo M, Poisa-Beiro L, Klebow S, Paterka M,
Yogev N, Tumani H, Furlan R, Siffrin V, Jonuleit H, Zipp F§, Waisman A§. 2013.
Modulation of dendritic cel properties by laquinimod as a mechanism for modulating
Multiple Sclerosis. Brain 136:1048-66
Roep BO, Buckner J, Sawcer S, Toes R, Zipp F. 2012. The problems and promises
of research into human immunology and autoimmune disease. Nature Med 18: 48-
53.
Siffrin, V, Radbruch H, Glumm R, Niesner R, Paterka M, Herz J, Leuenberger T,
Lehmann SM, Luenstedt S, Rinnenthal JL, Laube G, Luche H, Lehnardt S, Fehling H,
Griesbeck O, Zipp F. 2010. In vivo imaging of partial y reversible th17 cel -induced
neuronal dysfunction in the course of encephalomyelitis. Immunity 33: 424-436.
Siffrin V, Vogt J, Radbruch H, Nitsch R, Zipp F. 2010. Multiple sclerosis -candidate
mechanisms underlying CNS atrophy. Trends Neurosci 33: 202-10
Schulze-Topphoff U, Prat A, Prozorovski T, Siffrin V, Paterka M, Herz J, Bendix I,
Ifergan I, Schadock I, Mori MA, Van Horssen J, Schröter F, Han MH, Bader M,
Steinman L, Aktas O, Zipp F. 2009. Activation of kinin receptor B1 limits
encephalitogenic T lymphocyte recruitment to the central nervous system. Nature
Med 15: 788-793
Siffrin V, Brandt AU, Radbruch H, Herz J, Boldakowa N, Leuenberger T, Werr J,
Hahner A, Schulze-Topphoff U, Nitsch R, Zipp F. 2009. Differential immune cel
dynamics in the CNS cause CD4+ T cel compartmentalization. Brain 132: 1247-58
Prozorovski T, Schulze-Topphoff U, Glumm R, Baumgart J, Schröter F, Niemann O,
Siegert E, Bendix I, Brüstle O, Nitsch R, Zipp F§, Aktas O§. 2008. Sirt1 critical y
contributes to the redox-dependent fate of neural progenitors. Nature Cell Biol 10:
385-394 §equal y contributing
Paul F, Jarius S, Aktas O, Bluthner M, Bauer O, Appelhans H, Franciotta D, Bergamaschi R, Littleton E, Palace J, Seelig HP, Hohlfeld R, Vincent A, Zipp F. 2007.
Antibody to Aquaporin-4 in the Diagnosis of Neuromyelitis Optica. PLoS Med 4: 669-
674
Hoffmann O, Pril er J, Prozorovski T, Schulze-Topphoff U, Baeva N, Lunemann JD,
Aktas O, Mahrhofer C, Stricker S, Zipp F§, Weber JR§. 2007. TRAIL limits excessive
host immune responses in bacterial meningitis. J Clin Invest 117: 2004–2013
Zipp F, Aktas O. 2006. The brain as a target of inflammation: common pathways link
inflammatory and neurodegenerative diseases. Trends Neurosci 29: 518-527
Aktas O, Smorodchenko A, Brocke S, Infante-Duarte C, Prozorovski T, Meier S,
Osmanova V, Kwidzinski E, Pohl E, Beyer M, Bechmann I, Nitsch R, Zipp F. 2005.
Neuronal damage in autoimmune neuroinflammation mediated by the death ligand
TRAIL. Neuron 46: 421-432
Wandinger KP, Lünemann J, Wengert O, Bel mann-Strobel J, Aktas O, Weber A,
Grundström E, Ehrlich E, Wernecke KD, Volk HD, Zipp F. 2003. TNF-related
apoptosis inducing ligand (TRAIL) as a potential response marker for IFN-beta
therapy in multiple sclerosis. The Lancet 361, 2036-2043
Aktas O, Waiczies S, Smorodchenko A, Dörr J, Seeger B, Prozorovski T, Sal ach S,
Endres M, Brocke S, Nitsch R, Zipp F. 2003. Treatment of relapsing paralysis in
experimental encephalomyelitis by targeting Th 1 cel s through atorvastatin. J Exp
Med 197, 711-723
Diestel A, Aktas O, Hackel D, Häke I, Meier S, Raine CS, Nitsch R§, Zipp F§, Ul rich
O§. 2003. Activation of microglial poly(ADP-ribose)-polymerase-1 by cholesterol
breakdown products during neuroinflammation: a link between demyelination and
neuronal damage. J Exp Med 198: 1729-1740 §equal y contributing
Zipp, F, Weil JG, Einhäupl KM. 1999. No evidence for increased demyelinating
diseases induced by hepatitis B vaccination. Nature Med, 5, 964-965

Source: http://www.fzi.uni-mainz.de/Dateien/ENCV_Prof_Zipp.pdf